18 June 2018 in Nanoscale
Abdominal wall defect repair remains a major clinical need, and a particle-based controllable drug delivery system offers a solution to this problem. Here, we present a new type of hierarchically porous microparticles (HPMs) composed of poly(lactic-co-glycolic acid) (PLGA) and hollow mesoporous silica nanoparticles (HMSNs) for the delivery. The HPMs are generated by drying microfluidic emulsion templates of HMSNs-dispersed PLGA solution. The resultant HPMs have tailorable porous structures, that provide a three-hierarchy architecture for the controlled release of actives. The first hierarchy is formed for controlling the drug release via physical absorption as a result of the presence of the HMSNs in the HPMs. The second hierarchy channels with small pores scattered throughout the surface of the HPMs are formed during evaporation of the solvent. The third hierarchy with openings on the surface of the HPMs is formed as a result of the inner droplets leaking out of the double emulsion templates during the PLGA solidification. Thus, by manipulating the flow of solutions during the microfluidic emulsification, the porous structures of HPMs can be easily and precisely adjusted, and the loaded drugs are delivered at the required rate. These features of the HPMs make them ideal for repairing abdominal wall defects.
8 October 2018 in Advanced Healthcare Materials
31 July 2017 in Journal of International Medical Research
Objective: To evaluate the impact of inhibition of the receptor for advanced glycation end products (RAGE) on the outcome of bacterial sepsis in animal models. Methods: Relevant publications were identified by systematic searches of PubMed, ISI Web of Science and Elsevier-Scopus databases. Results: A total of Eleven studies with moderate quality were selected for analysis. A meta-analysis of survival rates revealed a significant advantage of RAGE inhibition in comparison with controls (HR 0.67, 95% CI 0.52–0.86). This effect was most pronounced in polymicrobial infection (HR 0.28, 95% CI 0.14–0.55), followed by Gram positive (G + ) bacterial infection (HR 0.70, 95% CI 0.50–0.97) and Gram negative (G − ) bacterial infection (HR 0.89, 95% CI 0.58–1.38). For G + bacterial infection, RAGE inhibition decreased bacterial outgrowth and dissemination, inflammatory cell influx, plasma cytokine levels, and pulmonary injury. Conclusions: RAGE inhibition appears to have a beneficial impact on the outcome of sepsis in animal models, although there are discrepancies between different types of infection.
3 May 2017 in Irish Journal of Medical Science (1971 -)